Inogen Inc INGN
We take great care to ensure that the data presented and summarized in this overview for Inogen Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INGN
View all-
Camber Capital Management LP Boston, MA2MShares$14.7 Million0.42% of portfolio
-
Black Rock Inc. New York, NY1.63MShares$12 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.46MShares$10.7 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD1.36MShares$9.96 Million0.3% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN849KShares$6.22 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA758KShares$5.56 Million0.02% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX631KShares$4.63 Million0.14% of portfolio
-
Jpmorgan Chase & CO New York, NY627KShares$4.6 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX608KShares$4.46 Million0.0% of portfolio
-
Fred Alger Management, LLC New York, NY601KShares$4.41 Million0.03% of portfolio
Latest Institutional Activity in INGN
Top Purchases
Top Sells
About INGN
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Insider Transactions at INGN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2025
|
Kevin Raymond Merrill Smith CEO and President |
BUY
Open market or private purchase
|
Direct |
11,709
+14.28%
|
$93,672
$8.56 P/Share
|
|
Mar 03
2025
|
Michael J. Bourque EVP, CFO & Treasurer |
BUY
Open market or private purchase
|
Direct |
3,000
+5.92%
|
$24,000
$8.32 P/Share
|
|
Mar 01
2025
|
Kevin Raymond Merrill Smith CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
39,797
-30.84%
|
$318,376
$8.33 P/Share
|
|
Mar 01
2025
|
Kevin Raymond Merrill Smith CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
55,475
+23.74%
|
$221,900
$4.17 P/Share
|
|
Mar 01
2025
|
Kevin Raymond Merrill Smith CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
28,333
+38.96%
|
-
|
|
Mar 01
2025
|
Michael J. Bourque EVP, CFO & Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,579
-34.0%
|
$228,632
$8.33 P/Share
|
|
Mar 01
2025
|
Michael J. Bourque EVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
48,225
+46.45%
|
$192,900
$4.17 P/Share
|
|
Mar 01
2025
|
Michael J. Bourque EVP, CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+49.41%
|
-
|
|
Mar 01
2025
|
Kevin P. Smith EVP, Bus Dev, GC & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
1,186
+50.0%
|
$9,488
$8.33 P/Share
|
|
Jan 31
2025
|
Mira Kirti Sahney |
BUY
Grant, award, or other acquisition
|
Direct |
9,112
+50.0%
|
-
|
|
Dec 01
2024
|
Gregoire Ramade Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,942
-41.0%
|
$116,478
$9.71 P/Share
|
|
Dec 01
2024
|
Gregoire Ramade Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,565
+50.0%
|
-
|
|
Dec 01
2024
|
Kevin Raymond Merrill Smith CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
13,779
-48.63%
|
$124,011
$9.71 P/Share
|
|
Dec 01
2024
|
Kevin Raymond Merrill Smith CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
28,333
+50.0%
|
-
|
|
Jun 05
2024
|
Heather D. Rider |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+27.52%
|
-
|
|
Jun 05
2024
|
Kevin M King |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+32.1%
|
-
|
|
Jun 05
2024
|
Glenn S Boehnlein |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+32.1%
|
-
|
|
Jun 05
2024
|
Elizabeth Mora |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+31.05%
|
-
|
|
Jun 05
2024
|
Mary Kay Ladone |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+32.1%
|
-
|
|
Jun 05
2024
|
Thomas A. West |
BUY
Grant, award, or other acquisition
|
Direct |
21,871
+34.97%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 245K shares |
|---|---|
| Exercise of conversion of derivative security | 166K shares |
| Open market or private purchase | 14.7K shares |
| Payment of exercise price or tax liability | 123K shares |
|---|---|
| Open market or private sale | 10K shares |